Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: ONC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BeOne Medicines Ltd. (ONC) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other documents filed with the Securities and Exchange Commission. BeOne is a Switzerland‑domiciled global oncology company whose American Depositary Shares are registered with the SEC, while its ordinary shares trade on the Hong Kong Stock Exchange and it also reports to the STAR Market in Shanghai.
Through its filings, BeOne reports on financial results, material agreements and corporate events. Recent Forms 8‑K referenced in the input include announcements of quarterly financial results, describing revenue growth driven primarily by BRUKINSA product sales and contributions from TEVIMBRA and in‑licensed products. Other 8‑K filings detail a royalty purchase agreement with Royalty Pharma tied to royalty rights on IMDELLTRA (tarlatamab) ex‑China net revenue, as well as the creation of related financial obligations and escrow arrangements.
Additional 8‑K reports cover topics such as the termination of a prior credit facility after arranging new financing, and the appointment and compensation terms of senior research and development leadership. The company also furnishes information about its interim reports filed with the STAR Market, including financial data prepared under China Accounting Standards and summaries of differences from U.S. GAAP.
On Stock Titan, users can review these ONC filings alongside AI‑generated summaries that explain the main points of each document in plain language. This includes highlighting key items in earnings‑related filings, summarizing the structure and implications of material agreements, and pointing out governance or leadership changes disclosed under Item 5.02 of Form 8‑K. Investors can also use the filings page to monitor how BeOne describes its oncology portfolio, collaborations and financial position over time, and to cross‑reference U.S. disclosures with the company’s press releases and non‑U.S. reporting.
Real‑time updates from EDGAR, combined with AI‑assisted overviews, help readers navigate lengthy filings and focus on sections most relevant to their interests, whether they are following BeOne’s hematology and solid tumor programs, its financing arrangements or its multi‑exchange reporting obligations.
BeOne Medicines Ltd. reported Q1 2026 revenue of $1.51B, up 35.5% from a year earlier, driven mainly by strong growth in BRUKINSA and TEVIMBRA. Net income rose sharply to $227.4M, compared with near breakeven a year ago, as higher sales and improved gross margin outpaced increased R&D and commercial spending.
Product revenue reached $1.49B, led by BRUKINSA at $1.09B (up 38.3%) and steady growth in Amgen-partnered products. Gross margin improved to 88.8% on a richer mix of BRUKINSA and efficiency gains. Operating cash flow climbed to $201.3M, lifting cash, cash equivalents and restricted cash to $4.85B, while total debt stood at $1.08B and the IMDELLTRA royalty financing liability at $904.4M.
BeOne Medicines reported a very strong first quarter of 2026, with total revenue of $1.51 billion, up 35% from the prior year. Net product revenue was $1.49 billion, driven mainly by oncology medicines.
Flagship BTK inhibitor BRUKINSA generated global sales of $1.1 billion, up 38%, including U.S. sales of $761 million (up 35%). TEVIMBRA reached $206 million in global sales, while Amgen in-licensed products contributed $142 million.
GAAP income from operations rose to $249.9 million and GAAP net income to $227.4 million, compared with nearly break-even a year earlier. GAAP diluted earnings were $1.96 per ADS, and non‑GAAP diluted earnings were $3.24 per ADS. Free cash flow improved to $160.5 million from negative levels.
The company raised full‑year 2026 guidance, now expecting total revenue of $6.3 billion–$6.5 billion and GAAP operating income of $750 million–$850 million. Management highlighted a broad oncology pipeline with multiple late‑stage milestones and regulatory decisions anticipated through 2026–2027.
BeOne Medicines Ltd. has released its 2026 proxy statement for the June 11, 2026 annual general meeting in Zurich, outlining 20 governance, compensation and capital-authorization proposals. Management highlights 2025 as a transformational year, with the company achieving GAAP profitability for the first time and generating meaningful cash flow.
The letter to shareholders emphasizes BeOne’s growing oncology franchise, led by BTK inhibitor BRUKINSA, which delivered $3.9 billion in 2025 global revenue, up 49% year over year. The company reports more than two million patients treated with its medicines and a workforce of nearly 12,000 employees across six continents.
Shareholders are asked to approve Swiss statutory financial statements, carry forward a Swiss standalone accumulated loss of $7.64 million, discharge directors and executives from liability under Swiss law, elect or re-elect ten directors, and ratify Ernst & Young entities as auditors. Additional resolutions seek say-on-pay approvals, updated equity plans, a mandate to issue up to 20% of issued shares, a 10% share repurchase mandate, and an authorization to allocate shares to Amgen to maintain its ownership percentage in future offerings.
Baker Bros. Advisors and affiliates report an 8.0% beneficial ownership stake in BeOne Medicines Ltd. (formerly BeiGene Ltd.) through ordinary shares and American Depositary Shares. The main adviser entities each report 115,462,653 Ordinary Shares, while Julian and Felix Baker each report 115,918,313 Ordinary Shares.
The filing notes BeOne’s redomiciliation to Switzerland and name change, and confirms that each ADS represents thirteen Ordinary Shares. It also discloses that Felix J. Baker has been nominated to serve as a director and Lead Director, while two existing Baker-affiliated directors are not standing for re-election. The Baker-managed funds state they hold their position for investment purposes but may increase or decrease holdings over time.
BeOne Medicines Ltd. SVP and General Counsel Lee Chan Henry exercised stock options and sold depositary shares in a planned transaction. On April 8, 2026, he exercised options for a total of 4,316 Ordinary Shares at exercise prices of $14.96, $16.41, and $12.23 per share.
These option exercises were represented through 332 American Depositary Shares (ADS), which were then sold at $311.59 per ADS under a pre-arranged Rule 10b5-1 trading plan. Each ADS represents 13 Ordinary Shares. After these transactions and related holdings, he directly holds 318,370 Ordinary Shares, indicating this was a routine liquidity event while maintaining a substantial equity stake.
OYLER JOHN reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that Chief Executive Officer John Oyler received two equity awards of Ordinary Shares as compensation. On March 6, 2026, he was granted 326,976 shares underlying earned performance share units that vest in 2027, and an additional 117,936 shares underlying earned performance share units that vest in 2028, in each case at no cash cost to him and subject to his continued service, with potential accelerated vesting upon a change of control or certain termination events. Following these awards, Oyler directly holds 5,609,275 Ordinary Shares. The filing also notes several indirect holdings in trusts and an LLC where he disclaims beneficial ownership, plus shares held for his benefit in a Roth IRA account.
Lee Chan Henry reported acquisition or exercise transactions in this Form 4 filing.
BeOne Medicines Ltd. reported that SVP and General Counsel Lee Chan Henry received two equity compensation awards on ordinary shares. These awards cover 65,390 and 29,874 shares underlying earned performance share units that vest in 2027 and 2028, subject to continued service. Following these grants, Henry directly holds 318,370 ordinary shares.
BeOne Medicines Ltd. reported that President and Global Head of R&D Wang Lai received equity compensation in the form of performance share units on ordinary shares. The grants cover 112,606 shares vesting in 2027 and 55,029 shares vesting in 2028, subject to continued service and possible accelerated vesting upon certain termination events. After these awards, Wang directly holds 1,619,059 ordinary shares.
He also has indirect exposure to 601,965 ordinary shares held by Wang Holdings LLC, for which he disclaims beneficial ownership, and an indirect economic interest in RMB Shares acquired through an employee participation plan, over which he has no voting or dispositive power.
BeOne Medicines Ltd. President and COO Wu Xiaobin reported equity awards and updated share holdings. He received two grants classified as acquisitions of ordinary shares, covering 168,922 and 78,624 shares tied to performance share units. These earned units will vest in 2027 and 2028 if he continues serving the company, with unvested amounts eligible for accelerated vesting upon certain termination events. Following these awards, he directly holds 1,216,524 ordinary shares, 12,365 American Depositary Shares (ADSs) directly, and 4,000 ADSs indirectly through his wife. Each ADS represents 13 ordinary shares.